Article thumbnail

CDK-Mediated Regulation of Cell Functions via c-Jun Phosphorylation and AP-1 Activation

By Tony J. Vanden Bush and Gail A. Bishop

Abstract

Cyclin-dependent kinases (CDKs) and their targets have been primarily associated with regulation of cell-cycle progression. Here we identify c-Jun, a transcription factor involved in the regulation of a broad spectrum of cellular functions, as a newly recognized CDK substrate. Using immune cells from mouse and human, and several complementary in vitro and in vivo approaches including dominant negative protein expression, pharmacologic inhibitors, kinase assays and CDK4 deficient cells, we demonstrate the ability of CDK4 to phosphorylate c-Jun. Additionally, the activity of AP-1, a ubiquitous transcription factor containing phosphorylated c-Jun as a subunit, was inhibited by abrogating CDK4. Surprisingly, the regulation of c-Jun phosphorylation by CDK4 occurred in non-dividing cells, indicating that this pathway is utilized for cell functions that are independent of proliferation. Our studies identify a new substrate for CDK4 and suggest a mechanism by which CDKs can regulate multiple cellular activation functions, not all of which are directly associated with cell cycle progression. These findings point to additional roles of CDKs in cell signaling and reveal potential implications for therapeutic manipulations of this kinase pathway

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3084876
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2009). A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma.
  2. (2001). A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells.
  3. (2003). A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun.
  4. (1999). Activation of the AP-1 transcription factor by inflammatory cytokines of the TNF family.
  5. (1991). An evolutionarily conserved cyclin homolog from Drosophila rescues yeast deficient in G1 cyclins.
  6. (2001). Anti-cytokine therapy in chronic destructive arthritis.
  7. (2001). Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases.
  8. (2004). AP-1 subunits: quarrel and harmony among siblings.
  9. (2003). AP-1: a double-edged sword in tumorigenesis.
  10. (2003). CD40-mediated transcriptional regulation of the IL-6 gene in B lymphocytes: involvement of NF-kappa B, AP-1, and C/EBP.
  11. (1999). CDK inhibitors: positive and negative regulators of G1-phase progression.
  12. (2003). Cdk2 knockout mice are viable.
  13. (2004). Cdk4 is indispensable for postnatal proliferation of the anterior pituitary.
  14. (2007). Clustering of phosphorylation site recognition motifs can be exploited to predict the targets of cyclin-dependent kinase.
  15. (1999). Cutting edge: contrasting roles of TNF receptorassociated factor 2 (TRAF2) and TRAF3 in CD40-activated B lymphocyte differentiation.
  16. (2000). Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development.
  17. (2010). Cyclin-dependent kinase inhibitors: a survey of recent patent literature.
  18. (2009). Cyclin-dependent kinase-3-mediated c-Jun phosphorylation at
  19. (1998). Cyclin-dependent kinases participate in death of neurons evoked by DNAdamaging agents.
  20. (2003). Cyclindependent kinase 2 is essential for meiosis but not for mitotic cell division in mice.
  21. (2006). Cyclindependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells.
  22. (2007). Cyclindependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus.
  23. (2008). Cyclindependent kinase inhibitors block leukocyte adhesion and migration.
  24. (2006). Cyclindependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis.
  25. (1994). Differential responses to Ig and class II-mediated signals in splenic B cell subsets from normal and autoimmune mice.
  26. (2006). Direct modulation of rheumatoid inflammatory mediator expression in retinoblastoma protein-dependent and -independent pathways by cyclindependent kinase 4/6.
  27. (1993). Distinct roles for cyclin-dependent kinases in cell cycle control.
  28. (2002). Granulocytemacrophage colony-stimulating factor (GM-CSF)-induced STAT5 activation and target-gene expression during human monocyte/macrophage differentiation.
  29. (2006). Inhibition of cancer cell growth by cyclin dependent kinase 4 inhibitors synthesized based on the structure of fascaplysin.
  30. (2003). Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events.
  31. (2003). JNK-independent activation of c-Jun during neuronal apoptosis induced by multiple DNA-damaging agents.
  32. (1999). Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia.
  33. Maini RN (2006) Interleukin-6: a new therapeutic target.
  34. Matsushime H,RousselMF(1992) Regulation ofCYL/cyclinD genesby colony-stimulating factor 1. Ciba Found Symp 170: 209–219; discussion
  35. (2003). progenitor numbers.
  36. (2004). Promiscuity rules?
  37. (2006). Rapid CD40-mediated rescue from CD95-induced apoptosis requires TNFR-associated factor-6 and PI3K.
  38. (2004). Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors?
  39. (2004). Requirement for TRAF3 in Signaling by LMP1
  40. (1998). Signal transduction by the c-Jun N-terminal kinase (JNK)–from inflammation to development.
  41. Smart TG (2005) HEK293 cell line: a vehicle for the expression of recombinant proteins.
  42. (2008). Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclindependent kinase inhibitors.
  43. (1999). Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity.
  44. (1996). The regulation of AP-1 activity by mitogen-activated protein kinases.
  45. (2008). TLR7 and CD40 cooperate in IL-6 production via enhanced JNK and AP-1 activation.
  46. (2006). Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.
  47. (2003). Tumor necrosis factor receptor-associated factor 2 (TRAF2)-deficient B lymphocytes reveal novel roles for TRAF2 in CD40 signaling.